免疫自体移植工程的长期结果。
Long-term outcome of immunologic autograft engineering.
作者信息
Porrata Luis F, Inwards David J, Ansell Stephen M, Micallef Ivana N, Johnston Patrick B, Villasboas Jose C, Paludo Jonas, Markovic Svetomir N
机构信息
Division of Hematology Department of Medicine Mayo Clinic Rochester Minnesota USA.
Department of Medical Oncology Mayo Clinic Rochester Minnesota USA.
出版信息
EJHaem. 2022 Feb 24;3(2):488-491. doi: 10.1002/jha2.404. eCollection 2022 May.
Our phase III trial reported that autograft-absolute lymphocyte count (A-ALC) improved survival post-autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) for a short-term follow-up of 2 years. We evaluated retrospectively in our phase III trial patients that the A-ALC still confers survival benefit with a longer follow-up. With a median follow-up of 127.6 months, patients infused with an A-ALC ≥ 0.5 × 10 cells/kg experienced better overall survival (HR = 0.392, 95% confidence of interval [CI]: 0.224-0.687, < 0.001) and progression-free survival (HR = 0.413, 95% CI: 0.253-0.677), < 0.0004). This study supports that A-ALC provides long-term survival benefit post APBHSCT.
我们的III期试验报告称，在自体外周血造血干细胞移植（APBHSCT）后的2年短期随访中，自体移植绝对淋巴细胞计数（A-ALC）改善了生存率。我们在III期试验患者中进行了回顾性评估，发现A-ALC在更长时间的随访中仍具有生存益处。中位随访时间为127.6个月，输注A-ALC≥0.5×10⁹细胞/千克的患者总体生存率更好（风险比[HR]=0.392，95%置信区间[CI]：0.224-0.687，P<0.001），无进展生存率也更好（HR=0.413，95%CI：0.253-0.677，P<0.0004）。本研究支持A-ALC在APBHSCT后提供长期生存益处。
Zotero 插件